Falling Costs Make Genomics (and Their ETFs) More Attractive than Ever

One of the most compelling elements in the genomics investment thesis is that costs are declining, making the next generation of healthcare solutions more accessible. That trend also benefits financial assets, such as the ARK Genomic Revolution Multi-Sector Fund (CBOE: ARKG). Many of the...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.